Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Change in Account Payables (2020 - 2025)

Historic Change in Account Payables for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$110000.0.

  • Foghorn Therapeutics' Change in Account Payables rose 9185.79% to -$110000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$239000.0, marking a year-over-year increase of 9215.11%. This contributed to the annual value of -$2.5 million for FY2024, which is 39255.32% down from last year.
  • Foghorn Therapeutics' Change in Account Payables amounted to -$110000.0 in Q3 2025, which was up 9185.79% from -$747000.0 recorded in Q2 2025.
  • Foghorn Therapeutics' Change in Account Payables' 5-year high stood at $1.7 million during Q1 2023, with a 5-year trough of -$1.4 million in Q2 2022.
  • In the last 5 years, Foghorn Therapeutics' Change in Account Payables had a median value of -$110000.0 in 2025 and averaged -$23842.1.
  • Within the past 5 years, the most significant YoY rise in Foghorn Therapeutics' Change in Account Payables was 84761.9% (2022), while the steepest drop was 39010.1% (2022).
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Change in Account Payables stood at -$21000.0 in 2021, then skyrocketed by 847.62% to $157000.0 in 2022, then crashed by 250.32% to -$236000.0 in 2023, then skyrocketed by 241.53% to $334000.0 in 2024, then tumbled by 132.93% to -$110000.0 in 2025.
  • Its last three reported values are -$110000.0 in Q3 2025, -$747000.0 for Q2 2025, and $284000.0 during Q1 2025.